Cargando…

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts

BACKGROUND: Anti-fibrotic drugs such as pirfenidone have been developed for the treatment of idiopathic pulmonary fibrosis. Because activated fibroblasts in inflammatory conditions have similar characteristics as cancer-associated fibroblasts (CAFs) and CAFs contribute actively to the malignant phen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mediavilla-Varela, Melanie, Boateng, Kingsley, Noyes, David, Antonia, Scott J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776434/ https://www.ncbi.nlm.nih.gov/pubmed/26935219 http://dx.doi.org/10.1186/s12885-016-2162-z

Ejemplares similares

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
por: Andersen, Stine, et al.
Publicado: (2019)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
por: Jin, Jin, et al.
Publicado: (2019)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1
por: Tao, Yijin, et al.
Publicado: (2020)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis
por: Bracco Gartner, Thomas C. L., et al.
Publicado: (2022)

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Correction to: Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents
por: Gu, Chenxi, et al.
Publicado: (2022)

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
por: Ferrara, Francesco, et al.
Publicado: (2020)

Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2
por: Antar, Samar A., et al.
Publicado: (2022)

Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G(1) Cell Cycle Arrest
por: Ishii, Kenichiro, et al.
Publicado: (2019)

A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2017)

Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
por: Fernández Pérez, Evans R., et al.
Publicado: (2021)

Connexin Hemichannel Activation by S-Nitrosoglutathione Synergizes Strongly with Photodynamic Therapy Potentiating Anti-Tumor Bystander Killing
por: Nardin, Chiara, et al.
Publicado: (2021)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Repurposing of Pirfenidone (Anti-Pulmonary Fibrosis Drug) for Treatment of Rheumatoid Arthritis
por: Gan, Donghao, et al.
Publicado: (2021)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

ABT-737 synergizes with Bortezomib to kill melanoma cells
por: Reuland, Steven N., et al.
Publicado: (2011)

Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step
por: Weiskirchen, Ralf
Publicado: (2016)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model
por: Soliman, Hatem, et al.
Publicado: (2015)

Cisplatin and CCNU synergism in spheroid cell subpopulations.
por: Durand, R. E.
Publicado: (1990)

The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro
por: Stougaard, Julie, et al.
Publicado: (2018)

Emetine Synergizes with Cisplatin to Enhance Anti-Cancer Efficacy against Lung Cancer Cells
por: Wu, Ti-Hui, et al.
Publicado: (2019)

A 3D culture system for evaluating the combined effects of cisplatin and anti-fibrotic drugs on the growth and invasion of lung cancer cells co-cultured with fibroblasts
por: Pan, Huei-Jyuan, et al.
Publicado: (2023)

Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells
por: Moraya, Amani I., et al.
Publicado: (2017)

Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
por: Mohamad Anuar, Nur Najmi, et al.
Publicado: (2020)

Rac Inhibition Reverses the Phenotype of Fibrotic Fibroblasts
por: Shi-wen, Xu, et al.
Publicado: (2009)

Dissecting Fibroblast Heterogeneity in Health and Fibrotic Disease
por: Shaw, Tanya J, et al.
Publicado: (2020)

In Vitro Effects of Pirfenidone on Cardiac Fibroblasts: Proliferation, Myofibroblast Differentiation, Migration and Cytokine Secretion
por: Shi, Qiang, et al.
Publicado: (2011)

Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts
por: Cui, Yingying, et al.
Publicado: (2020)

Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy
por: Fang, Qi, et al.
Publicado: (2022)

NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_97spggf1au97lenbuo1d2krjgc